Arnthor Aevarsson, Viggó T. Marteinsson, Gudmundur O. Hreggvidsson, Jakob

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

09/878,423

Group Art Unit:

Not assigned

Filed:

June 11, 2001

Examiner:

Not assigned

Title:

METHOD OF OBTAINING PROTEIN DIVERSITY

K. Kristjánsson and Olafur H. Fridjonsson

	, ,
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on 8/3//0/ Ellen Signature  Signature  Typed or printed name of person signing certificate	TE

RECEIVED ECH CENTER 1600/2900

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

•	•	*	
O	1	1	

lhis	Informatio	n Disc	losure	Statement	18	submitted:

[	]	under 37 CFR 1.129(a), or
		(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or

> A) or date of entry of the national -provisional application, including a

	(Within any one of the following time periods: three months of filing national application (other than a CPA) or stage in an international application; or before the mailing date of a first office action on the merits in a non-prov CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[ ]	under 37 CFR 1.97(d) together with:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Staten	ient Un	<u>der 37 CFR 1.97(e)</u>
[ ]	any co	tem of information contained in this Information Disclosure Statement was first cited in ommunication from a foreign patent office in a counterpart foreign application not more nree months prior to the filing of this Information Disclosure Statement; or
[]	comm knowl in the	m of information contained in this Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart foreign application, and, to the edge of the undersigned, after making reasonable inquiry, no item of information contained information disclosure statement was known to any individual designated in 37 CFR more than three months prior to the filing of this Information Disclosure Statement.
Statem	nent Un	der 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[ ]	comm was no	tem of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication of received by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.
[X]	Enclos	sed herewith is form PTO-1449:
	[X]	Copies of the cited references (AS4-AS6) are enclosed.
	[ ]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
	[]	The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:
		[ ] the explanation provided on the attached sheet.
		[ ] the explanation provided in the Specification.
		[ ] submission of the enclosed International Search Report.
		[ ] the enclosed English language abstract.

[X]	Applic	ant requests that the following non-published pending applications be considered:
Examiner's Initials		U.S. Patent Application No. 09/770,771, by Viggó T. Marteinsson, Cédric Hobel, Olafe H. Fridjonsson, Gudmunder O. Hreggvidsson, Jakob K. Kristjánsson, filed January 26, 2001, Docket No.: 2739.2004-000
		Examiner Date
	[X]	A copy of each file is attached for the above-cited application, including the current claims, is enclosed.
	[ ]	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.
The Exreferen	caminer	is requested to return a copy of the above list of pending applications indicating which re considered with the next office communication.
It is red	quested	that the information disclosed herein be made of record in this application.
Metho	d of pay	ment:
[ ]		k for the fee noted above is enclosed, or the fee has been included in the check with the panying Reply. A copy of this Statement is enclosed.
[ ]	Please enclose	charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is ed.
[X]	Please	charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.
		Respectfully submitted,
		HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
		Alice O. Carroll Registration No.: 33,542 Telephone: (781) 861-6240 Facsimile: (781) 861-9540
Lexing Dated:	<i>M</i> 3	ussachusetts 02421-4799  WST 30, 700

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2739.2004-001	APPLICAT 09/878	ion no.	CEIVEL	
THE TENTAL INFORMATION DISCLOSURE CITATION AN APPLICATION			APPLICANT Arnthor Aevarsson, et	al.	DEC	0 7 <sub>2001</sub>	
豆	0 4 20	3 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	acarr)	FILING DATE June 11, 2001	GROUP TO	CHCEN	ER 1600/2900
Cellia	(USE	seserar sheets in hece		PATENT DOCUMENTS	<u> </u>		** 1000/290/
	JEMIO		0.5.	PATENT BOCOMENTS	I		
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)	
	AS4			l genomics for science ural genomics supplemen			
	AT4	Hendrickson, W. F. 637-643 (2000).	A., "Synchro	otron crystallography",	Trends	Bioche	em Sci,
	AU4			of structural genomics			ıctural
	Cassetta, A., et al., "Development of instrumentation and methods for MAD and structural genomics at the SRS, ESRF, CHESS and Elettra facilities", J. Synchrotron Rad., 6:822-833 (1999).						
	AW4	Terwilliger, T.C., et al., "Class-directed structure determination: Foundation for a Protein Structure Initiative", Protein Sci, 1851-1856 (1998).					
	Rost, B., "Marrying structure and genomics", Structure, 6:259-263 (1998).						
	Brenner, S.E., "Target selection for structural genomics", Nature Structural Biology, Structural genomics supplement, 967-969 (2000).						
	AZ4	Terwilliger, T.C., "Structural genomics in North America", Nature Structural Biology, Structural genomics supplement, 935-939 (2000).					
	AR5	Hwang, K.Y., et al., "Structure-based identification of a novel NTPase from Methanococcus jannaschii", Nature Structural Biology, Structural genomics supplement, 691-696 (1999).					
	AS5			uctural genomics projec ural genomics supplemer			
	AT5	Shyamala, V., et reaction: SSP-PC		ome walking by single-p 84:1-8 (1989).	orimer p	oolymers	se chain
	AU5	Christendat, D., Structural Biolo		Structural proteomics o 903-909 (2000).	of an ar	chaeon'	', Nature
	AV5	bacterium <i>Therm</i> o	otoga marit. als strateg:	tate dehydrogenase from ima: the crystal structies for intrinsic prote 998).	ure at	2.1 Å	
	AW5	high thermostabi	ility of 1[4	, "Small structural cha 4Fe-4S]ferredoxin from ima, Structure, 4(11):1	the hyp	erther	mophilic
EXAMIN	IER		,	DATE CONSIDERED			

PTO-1449 REPRODUCED  SUPPLEMENTAL INFORMATION DISCLOSURE CITATION AN APPLICATION		ATTORNEY DOCKET NO. 2739.2004-001	APPLICATION NO. 09/878,423			
		APPLICANT Arnthor Aevarsson, et	DLU 0 7 2001			
(Use several sheets if necessary)			ssary)	FILING DATE June 11, 2001	GROUP TECH CENTER 1600/2	
U.S. PATENT DOCUMENTS						
		· · · · · · · · · · · · · · · · · · ·				
	j	OTHER DOCUMENTS	(Including Aut	L	Pages, Etc.)	
	AX5	Ther Documents (Including Author, Title, Date, Pertinent Pages, Etc.)  Evarsson, A., et al., "Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease", Structure, 8(3):277-291 (2000).				
	AY5	Kuntz, I.D., "Structure-Based Strategies for Drug Design and Discovery", Science, 257:1078-1082 (1992).				
	AZ5	Verlinde and Hol, "Structure-based drug design: progress, results and challenges", Structure, 2:577-587 (1994).				
	AR6	Ring, C.S., et al., "Structure-based inhibitor design by using protein models for the development of antiparasitic agents", Proc. Natl. Acad. Sci. USA, 90:3583-3587 (1993).				
	AS6	Evarsson, A., et al., "Crystal structure of 2-oxoisovalerate and dehydrogenase and the architecture of 2-oxo acid dehydrogenase multienzyme complexes", Nature Structural Biology, 6(8):785-792 (1999).				
EXAMINER DATE CONSIDERED						